1 min read
CG Oncology Shares Rise About 9% After Phase 3 Bladder Cancer Data
The data involved cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.

CG Oncology shares rose about 9% in Monday morning trading after the company posted Phase 3 data showing a statistically significant improvement in bladder cancer recurrence risk.
The data covered cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.